Harold Robert Meyer
The ADD Resource Center haroldmeyer@addrc.org
www.addrc.org
Reviewed: May13, 2026
Published: June 5, 2026
Listen to understand, not just to respond
You may have heard that ADHD brains “burn fuel differently”—a claim usually traced to a famous 1990 study showing reduced glucose metabolism in adults with hyperactivity of childhood onset. Three decades later, what does the evidence actually show? The picture is more complicated, more interesting, and—importantly—less clinically useful than the headlines suggest. Here is what brain-imaging research has and has not established about glucose metabolism and ADHD, and what that means for you.
Brain imaging using fluorodeoxyglucose positron emission tomography (FDG-PET) has produced suggestive but inconsistent evidence linking ADHD to altered cerebral glucose metabolism, with the most reproducible findings implicating fronto-striatal and premotor circuits. However, results vary substantially by age, sex, task, and study design, and chronic stimulant treatment does not produce robust metabolic shifts even when symptoms clearly improve. No FDG-PET signature is currently sensitive or specific enough to diagnose ADHD, and the technology remains a research tool rather than a clinical instrument.
Many adults with ADHD encounter brain-scan clinics, online influencers, or well-meaning relatives claiming that imaging can diagnose their condition or guide medication choice. Parents face the same pressure for their children. The reality is that no single brain-imaging finding—including glucose metabolism—has met the threshold for routine clinical diagnostic use. Understanding what the FDG-PET literature actually shows protects you from spending money and hope on tests that cannot deliver what they promise, while still respecting the genuine biology that underlies ADHD experience.
The widely cited 1990 Zametkin study examined 25 adults who had been hyperactive as children, had never been medicated, and were also biological parents of hyperactive children. During an auditory-attention task, these adults showed about 8% lower global cerebral glucose metabolism than 50 controls, with disproportionate reductions in premotor and superior prefrontal regions. The finding helped popularize the notion that ADHD reflects “underactive” frontal physiology and shaped public expectations about what brain imaging might eventually reveal.
Follow-up work complicated this picture quickly. In a 1993 study of teenagers, global metabolism did not differ between groups, though six of sixty regions—including the left anterior frontal lobe—showed reductions that inversely correlated with symptom severity. A larger replication in adolescent girls did not reproduce the original “globally low” pattern; instead, it found differences in lateralization across parietal and subcortical regions and identified sexual maturation as a meaningful confounder. These divergent findings reflect a methodological truth: FDG-PET results depend heavily on the task performed, the age and sex of the sample, and the ADHD subtype studied.
A counterintuitive finding deserves attention. In adults with ADHD treated chronically with methylphenidate or d-amphetamine, follow-up PET scans showed no robust changes in global metabolism and only minimal regional shifts—despite clear behavioral improvement. Either symptomatic benefit does not require sustained changes in glucose metabolism, or FDG-PET is simply not sensitive to the physiology that medication actually corrects. Both are likely true to some degree, and both have implications for how brain-imaging claims about treatment response should be interpreted.
Contemporary ADHD neuroscience emphasizes dysfunction across distributed networks—fronto-striatal circuits, the default mode network, and attention-control systems—captured primarily by resting-state functional MRI. These network-level findings are compatible with FDG-PET observations without being identical to them. Glucose metabolism on PET reflects regional synaptic energy demand; altered dopamine and noradrenergic signaling could plausibly shift that demand, but causality remains unresolved. Broader metabolic biology—including the gut-brain axis and short-chain fatty acid signaling—is expanding the picture but has not yet produced a clinically validated brain-glucose biomarker for ADHD.
You do not need a PET scan to confirm what a careful clinical evaluation already establishes. Symptoms, history, functional impairment, and thoughtful differential diagnosis remain the standard. Read more about why ADHD has no single definitive test.
Resist the marketing for proprietary brain scans claiming to diagnose ADHD in children. No imaging modality has the accuracy to justify that promise. A comprehensive evaluation by a qualified clinician remains the appropriate path.
The literature does not support FDG-PET as a clinical tool, but it does support continued attention to fronto-striatal physiology when interpreting research and counseling patients. The emerging field of precision medicine in ADHD is gradually clarifying which biological markers may eventually inform care—though we are not there yet.
Boonchooduang, N., Louthrenoo, O., Likhitweerawong, N., Thonusin, C., Chattipakorn, N., & Chattipakorn, S. C. (2023). Fecal short-chain fatty acids as potential biomarkers for attention-deficit/hyperactivity disorder. European Psychiatry, 66(S1), S833. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434378/
Ernst, M., Cohen, R. M., Liebenauer, L. L., Jons, P. H., & Zametkin, A. J. (1997). Cerebral glucose metabolism in adolescent girls with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 36(10), 1399–1406. https://pubmed.ncbi.nlm.nih.gov/9334553/
MacDonald, H. J., Kleppe, R., Szigetvari, P. D., & Haavik, J. (2024). The dopamine hypothesis for ADHD: An evaluation of evidence accumulated from human studies and animal models. Frontiers in Psychiatry, 15, 1492126. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11604610/
Matochik, J. A., Liebenauer, L. L., King, A. C., Szymanski, H. V., Cohen, R. M., & Zametkin, A. J. (1994). Cerebral glucose metabolism in adults with attention deficit hyperactivity disorder after chronic stimulant treatment. American Journal of Psychiatry, 151(5), 658–664. https://pubmed.ncbi.nlm.nih.gov/8166305/
Rubia, K. (2018). Cognitive neuroscience of attention deficit hyperactivity disorder (ADHD) and its clinical translation. Frontiers in Human Neuroscience, 12, 100. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5884954/
Zametkin, A. J., Liebenauer, L. L., Fitzgerald, G. A., King, A. C., Minkunas, D. V., Herscovitch, P., Yamada, E. M., & Cohen, R. M. (1993). Brain metabolism in teenagers with attention-deficit hyperactivity disorder. Archives of General Psychiatry, 50(5), 333–340. https://pubmed.ncbi.nlm.nih.gov/8489322/
Zametkin, A. J., Nordahl, T. E., Gross, M., King, A. C., Semple, W. E., Rumsey, J., Hamburger, S., & Cohen, R. M. (1990). Cerebral glucose metabolism in adults with hyperactivity of childhood onset. New England Journal of Medicine, 323(20), 1361–1366. https://pubmed.ncbi.nlm.nih.gov/2233902/
Curious about what an evidence-based ADHD evaluation actually involves—and what it does not require? Visit addrc.org for clear, current guidance, or contact us at info@addrc.org to learn how the ADD Resource Center can help you find your next step.
Harold Meyer founded The ADD Resource Center in 1993 and has spent more than 30 years translating the lived experience of ADHD into practical guidance for individuals and the professionals who support them. He co-founded CHADD of New York and led the Institute for the Advancement of ADHD Coaching. An author and international speaker, he has presented at the American Psychiatric Association Annual Meeting, CHADD national and local conferences, NYU Langone, Mount Sinai Medical Center, and Weill Cornell Medical College. Reach him at haroldmeyer@addrc.org.
_________________
info@addrc.org (mailto:info@addrc.org) • +1 (646) 205-8080
127 West 83rd St., Unit 133, Planetarium Station, New York, NY 10024-0840 USA
X | LinkedIn | Substack | ADHD Research and Innovation
Join Our Community
Subscribe to the ADD Resource Center newsletter for the latest resources and insights → Click here.
Disclaimers
Content is for educational purposes only and is not a substitute for professional advice. We strive for accuracy, though errors can occur. Some material may be AI-generated; please verify independently. Rejection Sensitive Dysphoria (RSD) is recognized by many providers but is not in the DSM.
In the USA and Canada, call or text 988 anytime for free mental health and suicide prevention support.
Privacy & Legal
Under GDPR and CCPA, you may request access to, correction of, or deletion of your personal data at info@addrc.org.
© 2026 Harold R. Meyer / ADD Resource Center. All rights reserved. Content may be shared only in complete, unaltered form with attribution. Reproduction or commercial use requires written permission (addrc@mail.com).
Withdrawal is one of the least reliable ways to prevent pregnancy, and the traits that…
Losing focus during sex is a predictable feature of how the ADHD brain regulates attention,…
The stakes are higher than an awkward evening. Couples affected by ADHD face elevated rates…
If you believe multitasking is your strength, you will build your workday around it: five…
If you have ADHD and read that half of people like you have anxiety, you…
Your fear is information about you, not a prediction about your child. Reasonable, consistently held…
